Haemonetics Corp.
HAE
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.08B
Close$
$151.80
130.4% upside
Current Fair Value
130.4% upsideUndervalued by 130.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.08 Billion |
|---|---|
| Enterprise Value | $4.06 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.05 |
| Beta | 0.53 |
| Outstanding Shares | 46,224,000 |
Return
| Return on Equity | 10.89% |
|---|---|
| Return on Assets | 4.06% |
| Return on Invested Capital | 7.23% |
Valuation & Multiples
| P/E Ratio | 32.21 |
|---|---|
| PEG | -23.91 |
| Price to Sales | 2.35 |
| Price to Book Ratio | 3.47 |
| Enterprise Value to Revenue | 3.04 |
| Enterprise Value to EBIT | 26.58 |
| Enterprise Value to Net Income | 41 |
| Total Debt to Enterprise | 0.3 |
| Debt to Equity | 1.37 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$1.28
Average shareholder expectationRevenue Estimate
$337.03 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$1.09
Average shareholder expectationRevenue Estimate
$329.71 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4255▲ 39.86% |
|---|---|
| Total Calls | 106,000▼ 90.12% |
| Total Puts | 45,100▲ 56.60% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 101.33%▼ 7.37% |
|---|---|
| Total Invested | $2.67B▼ 34.49% |
| Investors Holding | 331▼ 15.00% |
ESG Score
No data
About Haemonetics Corp.
CEO: Christopher Simon